Common Stock, par value $0.001 per share
- Symbol
- AVXL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Anavex Life Sciences Corp.
AVXLNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 11, 2026, Anavex Life Sciences Corp. (“Anavex” or the “Company”) issued a press release announcing the filing of the Company’s definitive proxy statement for its 2026 Annual Meeting of Stockholders (the “Press Release”).…
Press release in this filing
Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions →Company context
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.
Current securities
Registered securities in this filing
ANAVEX LIFE SCIENCES CORP. · 8-K · Filed 2026-08-11
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On August 11, 2026, Anavex Life Sciences Corp. (“Anavex” or
the “Company”) issued a press release announcing the filing of the Company’s definitive proxy statement for its 2026
Annual Meeting of Stockholders (the “Press Release”). The Press Release includes an open letter to Anavex’s stockholders
highlighting, among other things, plans to refresh Anavex’s Board of Directors at the 2026 Annual Meeting of Stockholders.
A copy of the Press Release is furnished as Exhibit 99.1 to this Current
Report and is incorporated herein by reference.
The information included in this Item 7.01, including Exhibit 99.1, shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 e7842_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders Files Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote “FOR” All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and Inexperienced Slate of Director Nominees NEW YORK, NY, August 11, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) scheduled to be held on September 24, 2026. Stockholders of record as of July 31, 2026 will be entitled to vote at the meeting. Anavex’s definitive proxy materials can be accessed for free by visiting EDGAR on the SEC website at www. SEC.gov. In conjunction with the definitive proxy statement filing, the…
Open exhibit ↗